anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a foot patch for treating diabetes, which relates to a high-voltage electrostatic bur bract. The invention belongs to a medical appliance which relates to a foot patch for treating feet with diabetes by a high-voltage electrostatic bur bract. In the invention, an electret has a high-voltage electrostatic voltage value of negative 400V, sponge particles soaked by liquor are embedded into an electret film, and one face of the film bulges to form the bur bract. Because bur discharge belongs to punctiform discharge, the discharge strength is high, and a wire is not easy to break, a better effect can be obtained by adopting a high-voltage bur electric field. An acupuncture eyelet is arranged on the bur bract so as to be convenient for the exudation of the liquor, and one face with the bur bract is fixed at an affected part by a double-face adhesive to form the high-voltage electrostatic bur bract electric field foot patch for the diabetes. The liquor is easy to form an atomization trend under the action of an electrostatic field, which is more beneficial to the affected part to absorb.
There is an urgent need for more knowledge on effective implementation strategies, as two-thirds of implementation efforts fail to achieve the intended change, and half have no effect on outcomes of interest. These implementation failures are partly due to the limited understanding of how implementation strategies work-the mechanisms of change through which implementation strategies affect implementation. This project will fill this research-gap by exploring mechanism of change during a cluster randomized controlled trial that compares the effectiveness of two implementation strategies for implementing the Guideline for the prevention of mental ill-health at the workplace in schools. Schools are chosen as the setting for implementation given the high prevalence of mental ill-health among teachers. Moreover, schools lack a structured approach to the prevention of mental ill-health. The aim of the project is to investigate how implementation strategies affect the defined mechanisms and guideline implementation. Mechanisms that will be tested include hypothesized mediators originating from the individual behavior change theory COM-B. The project will be conducted in public primary and secondary schools in four municipalities in Sweden. Data will be collected with mixed-methods from school-management and personnel at baseline, and different time-points during follow-up.
PROGLYCEM produces a dose-related increase in blood glucose, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect.

The hyperglycemic effect of PROGLYCEM begins within an hour and generally lasts no more than 8 hours in the presence of normal renal function.

PROGLYCEM decreases the excretion of sodium and water, resulting in fluid retention which may be clinically significant.

The hypotensive effect of PROGLYCEM is usually not marked (see ADVERSE REACTIONS).

Other pharmacologic actions of PROGLYCEM include increased pulse rate; increased serum uric acid levels due to decreased excretion; increased serum levels of free fatty acids’ decreased chloride excretion; decreased para-aminohippuric acid; (PAH) clearance with no appreciable effect on glomerular filtration rate.

The concomitant administration of a benzothiazide diuretic may intensify the hyperglycemic and hyperuricemic effects of PROGLYCEM. In the presence of hypokalemia, hyperglycemic effects are also potentiated.

PROGLYCEM-induced hyperglycemia is reversed by the administration of insulin or tolbutamide. The inhibition of insulin release by PROGLYCEM is antagonized by alpha-adrenergic blocking agents.

PROGLYCEM is extensively bound (more than 90%) to serum proteins and is excreted in the kidneys. The plasma half-life following intravenous administration is 28 ± 8.3 hours. Limited data on oral administration revealed a half-life of 24 and 36 hours in two adults. In four children aged 4 months to 6 years, the plasma half-life varied from 9.5 to 24 hours on long-term oral administration. The half-life may be prolonged following overdosage, and in patients with impaired renal function.
Psoriasis is a chronic skin inflammation characterized by dysregulated crosstalk between immune cells and keratinocytes. Here we show that the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is a key regulator of psoriatic inflammation in a mouse model. Platinum-doped positively charged carbon dots (Pt-CDs) were designed to inhibit the cGAS-STING pathway. By inhibiting the cGAS-STING pathway with Pt-CDs, the secretion of proinflammatory cytokines in macrophages was reduced, and the proinflammatory cytokines-induced breakdown of immunological tolerance and overexpression of chemokines in keratinocytes was restored, which reversed the homeostatic imbalance through breaking these cytokines-mediated intercellular positive feedback loop. Topical Pt-CDs treatment exhibited therapeutic effects in imiquimod-induced psoriasis mice without noticeable toxicity. The reversal of elevated expression of STING, phosphorylated STING, and downstream genes within psoriatic lesions indicates that Pt-CDs effectively inhibit the cGAS-STING pathway. This work suggests a promising strategy for psoriasis treatment by targeting the cGAS-STING pathway with Pt-CDs nanoinhibitor to restore skin homeostatic balance.
Screening for patients will take place in the oncological, gynecological medical, surgical departments of three hospitals in Copenhagen, Denmark among patients diagnosed with cancer. Patients eligible for the study will be informed about the study during hospital admission and asked to participate together with a close relative/family member. When written informed consent has been obtained from both patient and relative they will be asked to fill in questionnaires with background information about sociodemographic data, their physical and psychosocial functioning and quality of life EORTC (QLQ-C30/patient and SF36/relative), their symptoms of anxiety and depression (HAD Scale/patient and relative) and family satisfaction with health care professionals(FamCare/relative). When patients have been discharge from hospital to their own home the families are randomized to control or intervention group. First visit from the research nurse takes place no later than one week after randomization. Visits takes place week 1,4,7,10,13 and 16 after randomization. The questionnaires EORTC QLQ-C30 (patient), HAD Scale (patient and relative), SF 36 (relative) and FamCare (relative) are mailed by post to the families to be answered at week 9, 16 and 24 after randomization. Information about the amount of care the family receives from the municipality (standard homecare) will be obtained from municipal registers. Information about readmissions to hospital are obtained from hospital registers.

The research nurses has a minimum of one year experience within specialised palliative care. The nurses has also participated in a two day course on how to produce and utilise family assessment and have been introduced to the background theory on coping and family nursing.
PURPOSE: A personal dental medical history management system and a dental medical history management method are provided to manage a dental medical history of individuals by managing a personal dental medical treatment history and identifying material and manufacture applied to dental treatment. CONSTITUTION: An image recognition unit (210) captures a user authentication image by displaying in a user terminal. An authentication data transmission unit (240) transmits the authentication data determined by the authentication image to a dental management server. A first authentication and connection configuration unit authenticates the user terminal through a network. The first authentication and connection configuration unit configures channel connection of the user terminal to the network. A second authentication and connection configuration unit decides permission of access to the dental management server of a medical record system based on the authentication data received from the medical record system. The second authentication and connection configuration unit configures channel connection of the medical treatment information for the user authenticated through the authentication data. An authentication data storage unit (230) stores the authentication data temporarily or for a specific period. [Reference numerals] (210) Image recognition unit; (220) Authentication data determination unit; (230) Authentication data storage unit; (240) Authentication data transmission unit; (250) Channel connection configuration unit; (260) Request receiving unit; (270) Request transmitting and receiving unit; (280) Request display unit
Propionibacterium acnes (P. acnes) is an anaerobic and gram-positive bacterium involved in the pathogenesis and inflammation of acne vulgaris. This study particularly focuses on the antimicrobial effect of Lacticaseibacillus paracasei LPH01 against P. acnes, a bacterium that causes acne vulgaris. Fifty-seven Lactobacillus strains were tested for their ability to inhibit P. acnes growth employing the Oxford Cup and double dilution methods. The cell-free supernatant (CFS) of L. paracasei LPH01 demonstrated a strong inhibitory effect, with an inhibition zone diameter of 24.65 ± 0.27 mm and a minimum inhibitory concentration of 12.5 mg/mL. Among the CFS, the fraction over 10 kDa (CFS-10) revealed the best antibacterial effect. Confocal laser scanning microscopes and flow cytometry showed that CFS-10 could reduce cell metabolic activity and cell viability and destroy the integrity and permeability of the cell membrane. A scanning electron microscope revealed that bacterial cells exhibited obvious morphological and ultrastructural changes, which further confirmed the damage of CFS-10 to the cell membrane and cell wall. Findings demonstrated that CFS-10 inhibited the conversion of triglycerides, decreased the production of free fatty acids, and down-regulated the extracellular expression of the lipase gene. This study provides a theoretical basis for the metabolite of L. paracasei LPH01 as a potential antibiotic alternative in cosmeceutical skincare products.
South Asians (SA) have 2-4 fold higher risk of type 2 diabetes and develop the disease at lower body weights and younger ages than white Europeans. Lower cardiorespiratory fitness and capacity for muscle fat oxidation contributes substantially to SAs' greater insulin resistance, the extent to which this can be improved by exercise training is unclear. This randomised controlled trial will investigate the effects of a 12-week aerobic or resistance exercise training intervention on insulin sensitivity (hyperinsulinaemic-euglycaemic clamp) in South Asian adults (22 control, 22 aerobic exercise group and 22 resistance exercise group). The study will also explore the mechanisms within skeletal muscle which mediate these changes by evaluating aerobic and resistance exercise-training induced changes: in basal and insulin-stimulated microvascular blood volume (using contrast-enhanced ultrasound); skeletal muscle mitochondrial function; and lipid droplet morphology and spatial interaction with mitochrondria, muscle fibre capillarisation, endothelial content of key enzymes controlling dilation/constriction and GLUT-4 translocation (using confocal immunofluorescence microscopy and transmission electron microscopy methods). Thus, this work will integrate physiological and molecular data to determine the extent to which exercise training can improve insulin sensitivity in SA and the mechanisms underpinning this improvement. This knowledge is important for optimising diabetes prevention interventions in SAs and identification of potential novel therapeutic targets.
The current standard for assessment of rejection in lung transplants is a transbronchial biopsy (TBB) interpreted by histology according to International Society of Heart and Lung Transplantation (ISHLT) guidelines. This has considerable error rates, many due to the high disagreement among pathologists. There is a need for new methods of assessing TBBs. In addition, the emergence of blood donor-derived cell-free DNA (dd-cfDNA) measurement offers a new opportunity for screening for rejection. To address the unmet need for precision and accuracy, the Alberta Transplant Applied Genomics Centre (ATAGC, University of Alberta) has developed a new diagnostic system - the Molecular Microscope® Diagnostic System (MMDx), which uses microarrays to define the genome-wide gene expression and interpret lung transplant rejection and injury ((chronic lung allograft dysfunction (CLAD) related changes)). Now a new screening test is being introduced: the monitoring of dd-cfDNA released in the blood by the heart during rejection. The Natera Inc dd-cfDNA Prospera® test is based on the massively multiplex polymerase chain reaction that targets 13,392 single nucleotide polymorphisms and targeted sequences are quantified by Next Generation Sequencing. The Prospera® test has been done on kidney transplant recipients and detected "active rejection" and differentiated it from borderline rejection and no rejection. However, Prospera® test was not examined (the dd-cfDNA results) in lung transplant recipients. dd-cf-DNA test for lung transplants must now be calibrated against MMDx that is based on global gene expression, the new standard for biopsy interpretation. The present study will calibrate centrally measured (Natera Inc) dd-cfDNA levels obtained at the time of an indication or protocol biopsy against the MMDx measurements of T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR-like) and tissue injury. The present study will compare dd-cfDNA and MMDx in 600 prospectively collected biopsies for clinical indications and protocol, and accompanying 1800 blood samples, to calibrate the dd-cfDNA (Natera Inc.) levels against the MMDx biopsy diagnoses of TCMR, ABMR-like (and its stages), and injury, as well as central assessment of Human Leukocyte Antibody (HLA) antibody (One Lambda), interpreted centrally as donor specific antibody (DSA) based on the tissue typing results. This study is an extension of the INTERLUNG ClinicalTrials.gov identifier: NCT02812290.

Currently the study accrued 100 TBBs and 64 corresponding blood samples for dd-cfDNA test.
PURPOSE:To produce inexpensively a black pigment having high safety and a reduced heavy metal content, by reducing orthotitanic acid powder by heating it in an ammonia gas atmosphere. CONSTITUTION:TiO2 or titanium hydroxide is boiled in an aq. alkaline soln. The product is washed with water to remove salts and dried. The resulting orthotitanic acid is heated at 600-900 deg.C in an ammonia gas atmosphere. The resulting powder is reduced to such an extent that the blackness (L value) is lower than 13, thus obtaining a black pigment having a lead content of 5-11ppm.
Composition comprises a peptide or polypeptide or a biologically active derivative, having 4-50 amino acid residues, preferably 4-8 amino acid residues, of which a sequence comprises amino acid (I). Cosmetic or pharmaceutical composition comprises a peptide or polypeptide or a biologically active derivative, having 4-50 amino acid residues, preferably 4-8 amino acid residues, of which a sequence comprises amino acid of formula (AA) n-Trp-X 1-X 2-X 3-(AA) p (I). X 1arginine or lysine; X 2aliphatic amino acid (Leu, Ile, Val or Ala); X 3aspartic acid or glutamic acid; AA : amino acid or its derivatives; and n and p : 0-4. An independent claim is included for a process for cosmetic treatment comprising applying the composition on topically on a zone to be treated. ACTIVITY : Dermatological . MECHANISM OF ACTION : None given. Tests details are described but no results given.
A Fisher Paykl humidifier will be used for high flow humidification along with a flow meter and oxygen blender. A vibrating mesh nebulizer will be connected between the flow meter and the humidifier as per routine practice. Oxygen flow will be set to 2L/kg/min (max 60L/min) and patient will be fitted with appropriately sized nasal prongs.
PURPOSE: A composition containing glycyrrhizic acid for protecting nerve is provided to treat brain injury and nervous injury and to suppress infiltration of neutrophil white blood cells. CONSTITUTION: A composition for protecting nerve contains glycyrrhizic acid or pharmaceutically acceptable salt thereof as an active ingredient. The glycyrrhizic acid is denoted by chemical formula 1. The composition is used for treating and preventing ischemic brain diseases. The ischemic brain diseases include stroke, cerebral hemorrhage, cerebral infarction, head injury, Alzheimer, vascular dementia, creutzfeldt-Jakob disease, and coma. A health food for protecting nerve contains glycyrrhizic acid or pharmaceutically acceptable salt thereof as an active ingredient.
The aim of administering systemic therapy prior to surgery is to make a locally advanced tumor operable or to allow conservative surgery in the case of a T2-T3 tumor. Therefore, treatment is expected to induce a maximum tumor shrinkage within a short period. In addition and based on the anti-angiogenic MoA, bevacizumab (Avastin) is to be administered as early as possible during the disease stages. Bevacizumab has already been tested in the neoadjuvant setting with encouraging results. In a first trial patients with inoperable locally advanced breast cancer received docetaxel with or without bevacizumab with five clinical Complete Responses and 24 Partial Responses. In a second trial there was also reported the results of the combination of bevacizumab with doxorubicin and docetaxel for the treatment of inflammatory breast cancer. Then, a set of studies of primary therapy exploring the activity of different regimens have confirmed the role of baseline pathological features of the tumor in predicting the responsiveness to primary therapy. A 22% pathological complete responses (pCR) rate has been achieved in a study combining bevacizumab together with Xeloda and Taxotere suggesting that bevacizumab addition to chemotherapy in the neoadjuvant treatment is feasible showing promising activity while no unexpected toxicities were reported.

Thus, a very high interest exists from our clinicians mostly within our cooperative groups which cover the largest national oncology centers to be involved and run such a study.
Methods, systems, and software are provided for determining a relationship between a subject and a health entity. An electronic health record (EHR) for the subject is split into sections by detecting delineating section headers, and sections are subdivided into text spans. Text spans are filtered by language pattern recognition into a set of text spans having an expression related to the health entity. The natural language context of the expression in each text span in the set is evaluated to obtain a corresponding scoring representation. Scoring representations are inputted into a model comprising a plurality of parameters. The model outputs, for each text span in the set, at least a prediction that the text span is associated with the health entity. Models for determining relationships between subjects and health entities and methods for training models to determine relationships between subjects and health entities are also provided.
The invention relates to the technical field of microorganisms, and particularly relates to lactobacillus reuteri SF-L-25 with a helicobacter pylori inhibiting function and application thereof. The lactobacillus reuteri SF-L-25 is preserved in China general microbiological culture Collection center (CGMCC) under No. 26 of 10 months in 2020, and the preservation numbers are as follows: CGMCC No. 20956; classified and named as Lactobacillus reuteri (Lactobacillus reuteri); and (4) storage address: xilu No. 1 Hospital No. 3, Beijing, Chaoyang, North; the Lactobacillus reuteri SF-L-25 strain provided by the invention is obtained by separating and screening healthy human gastric mucus, has high safety and strong stability, inhibits the growth of helicobacter pylori and urease activity, and effectively solves the problems of adverse reactions such as gastrointestinal dysfunction, gastrointestinal flora imbalance and the like caused by long-term unreasonable use of antibiotics in the process of preventing and treating helicobacter pylori infection; meanwhile, the lactobacillus reuteri SF-L-25 has obvious functional characteristics, so that the lactobacillus reuteri SF-L-25 has wide application value in probiotic solid beverages.
Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate in the postmarketing setting. The onset has ranged from a few days to several months after initiation of treatment with dimethyl fumarate. Signs and symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal and elevation of total bilirubin to greater than 2-fold the upper limit of normal have been observed. These abnormalities resolved upon treatment discontinuation. Some cases required hospitalization. None of the reported cases resulted in liver failure, liver transplant, or death. However, the combination of new serum aminotransferase elevations with increased levels of bilirubin caused by drug-induced hepatocellular injury is an important predictor of serious liver injury that may lead to acute liver failure, liver transplant, or death in some patients.

Elevations of hepatic transaminases (most no greater than 3 times the upper limit of normal) were observed during controlled trials [see Adverse Reactions ( 6.1)] . 

Obtain serum aminotransferase, alkaline phosphatase (ALP), and total bilirubin levels prior to treatment with dimethyl fumarate and during treatment, as clinically indicated. Discontinue dimethyl fumarate delayed-release capsules if clinically significant liver injury induced by dimethyl fumarate delayed-release capsules is suspected.
BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is a rare hematological disorder. The occurrence of TTP subsequent to an emergent aortic valve replacement after a TAVR procedure is exceedingly uncommon with only a few reported cases worldwide.
CASE PRESENTATION: We report the case of a 70-year-old female patient diagnosed with aortic insufficiency. Following a transcatheter aortic valve replacement, she underwent emergency aortic valve replacement under cardiopulmonary bypass on the subsequent day due to heart valve displacement. The postoperative diagnosis revealed TTP and symptomatic treatment involving plasma exchange was administered. After demonstrating steady improvement, the patient was eventually discharged.
CONCLUSION: Aortic valve replacement after TAVR is a high-risk procedure and increases susceptibility for developing secondary TTP. The diagnosis and treatment of secondary TPP is considerably challenging, and early diagnosis with symptomatic treatment including plasma exchange can increase patient survival.